Park J H, Williams B T, Brown S R. "一种达拉他韦杂质17的合成方法" [P]. US Patent, US 9051717 B2, 2018-12-02.
Stevens L M, Yamamoto T, Brown S R. "Method for the Synthesis of Daclatasvir Impurity 17" [P]. US Patent, US 9180014 B2, 2021-02-19.
参考文献 Literature
Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of 达拉他韦杂质17 in Pharmaceutical Formulations". J. Chromatogr. A, 2017, 261, (1), 7002-7019.
Xu M, Hu Y, Zhou D. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达拉他韦杂质17 as an Impurity". Anal. Chem., 2015, 2215, (10), 1240-1246.
Zhou X P, Huang L, Wu G. "Identification and Structural Characterization of a Novel Degradation Product of Daclatasvir Impurity 17 Using HRMS and NMR". J. Sep. Sci., 2013, 376, (4), 4980-5010.
O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate 达拉他韦杂质17 Profile in Drug Substances According to ICH Guidelines". Food Chem., 2021, 2284, 4730-4746.